CA2608751A1 - Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling - Google Patents

Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling Download PDF

Info

Publication number
CA2608751A1
CA2608751A1 CA002608751A CA2608751A CA2608751A1 CA 2608751 A1 CA2608751 A1 CA 2608751A1 CA 002608751 A CA002608751 A CA 002608751A CA 2608751 A CA2608751 A CA 2608751A CA 2608751 A1 CA2608751 A1 CA 2608751A1
Authority
CA
Canada
Prior art keywords
seq
monoclonal antibody
sequence shown
cell
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002608751A
Other languages
English (en)
French (fr)
Inventor
Sharon Lea Aukerman
Bahija Jallal
Mohammad Luqman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Xoma Technology Ltd USA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2608751A1 publication Critical patent/CA2608751A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
CA002608751A 2005-05-18 2006-05-18 Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling Abandoned CA2608751A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US68258205P 2005-05-18 2005-05-18
US60/682,582 2005-05-18
US74928505P 2005-12-09 2005-12-09
US60/749,285 2005-12-09
PCT/US2006/019414 WO2006125143A2 (en) 2005-05-18 2006-05-18 Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling

Publications (1)

Publication Number Publication Date
CA2608751A1 true CA2608751A1 (en) 2006-11-23

Family

ID=37022828

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002608751A Abandoned CA2608751A1 (en) 2005-05-18 2006-05-18 Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling

Country Status (6)

Country Link
US (2) US8337851B2 (cg-RX-API-DMAC7.html)
EP (1) EP1894012A2 (cg-RX-API-DMAC7.html)
JP (2) JP5208730B2 (cg-RX-API-DMAC7.html)
AU (1) AU2006247067B2 (cg-RX-API-DMAC7.html)
CA (1) CA2608751A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006125143A2 (cg-RX-API-DMAC7.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006247067B2 (en) * 2005-05-18 2012-06-07 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
NZ592159A (en) 2005-12-09 2012-12-21 Amc Amsterdam Means and methods for influencing the stability of antibody producing cells
EP1987161A4 (en) * 2006-01-20 2009-06-24 Univ Mcgill METHOD FOR IDENTIFYING CD40-SENSITIVE CELLS
AR060487A1 (es) 2006-04-21 2008-06-18 Xoma Technology Ltd Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
ES2318616T3 (es) * 2006-06-01 2009-05-01 Cellzome Ag Metodos para la identificacion de moleculas que interactuan con zap-70 y para la purificacion de zap-70.
CN101910414B (zh) * 2007-11-07 2016-01-13 健泰科生物技术公司 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法和组合物
CN102459639A (zh) 2009-04-18 2012-05-16 健泰科生物技术公司 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法
US9085798B2 (en) 2009-04-30 2015-07-21 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US9273118B2 (en) 2009-07-15 2016-03-01 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
SG10201405069QA (en) * 2009-08-25 2014-10-30 Berg Llc Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10)
WO2011127099A1 (en) 2010-04-05 2011-10-13 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
CN102947706B (zh) * 2010-04-19 2018-04-13 生物标志物策略公司 预测药物敏感性、抗性和疾病进展的组合物和方法
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
CN103429615B (zh) 2010-12-02 2018-03-16 埃姆医疗有限公司 用于生产高亲和力抗体的方式和方法
EP2694709B1 (en) 2011-04-08 2016-09-14 Prognosys Biosciences, Inc. Peptide constructs and assay systems
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
EP4592400A3 (en) 2012-10-17 2025-10-29 10x Genomics Sweden AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
EP3736573A1 (en) * 2013-03-15 2020-11-11 Prognosys Biosciences, Inc. Methods for detecting peptide/mhc/tcr binding
CA2916662C (en) 2013-06-25 2022-03-08 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US10288608B2 (en) 2013-11-08 2019-05-14 Prognosys Biosciences, Inc. Polynucleotide conjugates and methods for analyte detection
WO2015085171A1 (en) * 2013-12-06 2015-06-11 Adventist Health Systems/Sunbelt, Inc. Role of mcp-1 in relapse of acute myeloid leukemia after hematopoietic stem cell transplantation
CA2938193C (en) 2014-01-31 2023-05-02 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
ES2833543T3 (es) * 2014-10-24 2021-06-15 Koninklijke Philips Nv Evaluación de la actividad de la ruta de señalización celular de TGF usando modelos matemáticos de la expresión de genes diana
EP3901282B1 (en) 2015-04-10 2023-06-28 Spatial Transcriptomics AB Spatially distinguished, multiplex nucleic acid analysis of biological specimens
WO2017024019A1 (en) * 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
DK3359688T3 (da) * 2015-10-05 2021-08-23 Biogen Ma Inc Molekylære signaturer til anvendelse til diagnose og analyse af respons på behandling af autoimmune sygdomme
CN114755412A (zh) * 2016-10-23 2022-07-15 伯克利之光生命科技公司 筛选b细胞淋巴细胞的方法
US20210215697A1 (en) * 2018-05-14 2021-07-15 Bergenbio Asa Serum Biomarkers
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
WO2020243579A1 (en) 2019-05-30 2020-12-03 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
EP4414459B1 (en) 2020-05-22 2025-09-03 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
EP4600376A3 (en) 2020-06-02 2025-10-22 10X Genomics, Inc. Spatial transcriptomics for antigen-receptors
AU2021283174A1 (en) 2020-06-02 2023-01-05 10X Genomics, Inc. Nucleic acid library methods
EP4421186B1 (en) 2020-06-08 2025-08-13 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
CN113684180B (zh) * 2021-08-31 2023-05-26 山东大学第二医院 一种提高骨髓瘤杀伤活性的nk细胞制备方法
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
CN115845063B (zh) * 2022-12-20 2024-07-09 中国医学科学院医学生物学研究所 与急性t淋巴细胞白血病治疗相关的靶点cd40lg及其应用
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024173352A2 (en) * 2023-02-13 2024-08-22 Shattuck Labs, Inc. Methods of treating cancer with a sirp1a-based chimeric protein

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2330916C (en) * 1998-05-19 2011-04-05 Research Development Foundation Triterpene compositions and methods for use thereof
AU2001259142C1 (en) 2000-04-25 2006-11-23 Biogen Idec Inc. Intrathecal administration of rituximab for treatment of central nervous system lymphomas
EP1322383B9 (en) * 2000-10-02 2006-09-06 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AU2003304386A1 (en) * 2002-10-30 2005-02-25 The Center For Blood Research, Inc. Methods for treating and preventing apoptosis-related diseases using rna interfering agents
JP4609930B2 (ja) * 2002-12-11 2011-01-12 ベンタナ・メディカル・システムズ・インコーポレーテッド Ｈｅｒ−２指向性治療に対する応答を予測する方法
GB0301566D0 (en) * 2003-01-23 2003-02-26 Eirx Therapeutics Ltd Kinasaes and GPCRs involved in apoptosis
ATE447412T1 (de) * 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
WO2005044307A2 (en) * 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for b cell-related cancers
US20090215895A1 (en) * 2004-01-30 2009-08-27 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
US20070292439A1 (en) * 2004-04-27 2007-12-20 Novartis Vaccines And Diagnostics, Inc. Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
AU2006247067B2 (en) * 2005-05-18 2012-06-07 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling

Also Published As

Publication number Publication date
US20090041773A1 (en) 2009-02-12
WO2006125143A3 (en) 2007-03-22
JP2008539794A (ja) 2008-11-20
US8337851B2 (en) 2012-12-25
WO2006125143A2 (en) 2006-11-23
JP5208730B2 (ja) 2013-06-12
JP2013057686A (ja) 2013-03-28
EP1894012A2 (en) 2008-03-05
AU2006247067B2 (en) 2012-06-07
US20130230528A1 (en) 2013-09-05
AU2006247067A1 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
AU2006247067B2 (en) Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling
US8333970B2 (en) Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject having an inflammatory or autoimmune disease
US10647771B2 (en) Antibody that binds to human programmed death ligand 2 (PD-L2) and uses thereof
AU2014339900B2 (en) Anti-PD-L1 monoclonal antibodies and fragments thereof
AU2009239437B2 (en) Levels of BCMA protein expression on B cells and use in diagnostic methods
AU2006308606C1 (en) Uses of anti-CD40 antibodies
US20230331847A1 (en) Anti-phosphotyrosinylated programmed death 1 (pd-1) monoclonal antibodies, methods of making and methods of using thereof
RU2431676C2 (ru) Анализы и способы с применением биомаркеров
CA2741489A1 (en) Methods, compositions, and kits for diagnosing, monitoring, and treating disease
CN118994395A (zh) Vista受体
HK1110942B (en) Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
WO2023144303A1 (en) Cd38 as a biomarker and biotarget in t-cell lymphomas

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20161107